Prognostic Study Correlates TSP and Clinical Outcomes in Ovarian Cancer

home / oncclub / prognostic-study-correlates-tsp-and-clinical-outcomes-in-ovarian-cancer

Emil Lou, MD, PhD, FACP, discusses data from a study evaluating whether tumor-stroma proportion can predict chemoresistance and other outcomes in patients with ovarian cancer.

Emil Lou, MD, PhD, FACP, of University of Minnesota Medical School

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Emil Lou, MD, PhD, FACP

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

May 15th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Emil Lou, MD, PhD, FACP, of the University of Minnesota Medical School

Prognostic Study Correlates TSP and Clinical Outcomes in High-Grade Serous Ovarian Cancer

May 17th 2024

TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.